Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2018

View Archived Issues

Clinigen and Mitsubishi Tanabe Pharma partner for European Managed Access Program for edaravone

Cosmo Pharmaceuticals receives FDA complete response letter for Methylene Blue MMX

FDA grants breakthrough therapy designation to Lenti-D investigational gene therapy

Lava Therapeutics to advance its bispecific gamma-delta T cell engager platform

FDA grants breakthrough therapy designation for Tafamidis

FDA accepts NDA for Zynquista as potential treatment for type 1 diabetes

U.K. Government and the Bill & Melinda Gates Foundation join CARB-X partnership

Spero presents positive top-line data for SPR-741 and SPR-206

FDA accepts supplemental BLA and grants priority review for pediatric use of Coagadex

IFB-088 to enter phase I clinical testing

New hedgehog signaling inhibitors presented by e-Therapeutics

Ache Laboratorios Farmaceuticos divulges melatonin MT1 and MT2 receptor agonists

Carna Biosciences and Kitasato Institute discover antimalarials

RARI-049, a novel Nampt inhibitor for treating pulmonary hypertension

Hefei Co-Source Pharmaceuticals and Anhui Blooming Drug Safety Evaluation patent steroids

Center for Translational Drug Development synthesizes ROCK1/2 inhibitors

Plant Advanced Technologies patents quinic acid derivatives

PanOptica initiates phase I/II trial of PAN-90806 in wet AMD

FDA approves Yonsa for metastatic CRPC

Targeting TGF-beta-1 prevents pulmonary fibrosis in rats

Clinical results reported for bifunctional short-hairpin RNA for Ewing's sarcoma

DSMB recommends continuation of phase II study of Xanamem in Alzheimer's disease

Esperion's third pivotal study of bempedoic acid meets primary endpoint

MIW-815 elicits strong and durable cancer immunity

Bicycle Therapeutics expands collaboration with AstraZeneca

European Commission approves Sandoz's infliximab biosimilar Zessly

NIAID initiates phase I study of SeVRSV vaccine

Apogenix working towards conditional MAA submission for asunercept in E.U.

Favipiravir shows in vitro and in vivo antiviral activity against henipaviruses

Translate Bio begins first-in-human study of MRT-5005 in cystic fibrosis

MedImmune begins first-in-human study of MEDI-5752 in advanced solid tumors

NIH grant supports Thetis' development of TP-252 for ulcerative colitis

Golodirsen receives FDA orphan designation for Duchenne's muscular dystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...